Hemophilia A. ReGenX’s direct and indirect licensors retain the following rights with respect to the Sublicensed Technology: to the extent Sublicensed Technology pertains to recombinant adeno-associated virus serotype 8, an exclusive, sublicensable right to make, have made, use, sell, offer for sale, and import products for the treatment of hemophilia A. *** Confidential Treatment Requested ***
Appears in 4 contracts
Samples: Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.), Collaboration and License Agreement (Dimension Therapeutics, Inc.), Collaboration and License Agreement (Dimension Therapeutics, Inc.)
Hemophilia A. ReGenX’s direct and indirect licensors retain the following rights with respect to the Sublicensed Technology: to the extent Sublicensed Technology pertains to recombinant adeno-associated virus serotype 8, an exclusive, sublicensable right to make, have made, use, sell, offer for sale, and import products for the treatment of hemophilia A. *** Confidential Treatment Requested ***A.
Appears in 1 contract
Samples: Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.)
